(Q36462566)

14 August 2017

title

Augmentation and combination strategies for depression (English)

1 reference

14 August 2017

Charles DeBattista

1

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 May 2006

1 reference

Journal of Psychopharmacology

14 August 2017

published in

1 reference

14 August 2017

volume

20

1 reference

14 August 2017

issue

3 Suppl

1 reference

14 August 2017

page(s)

11-18

1 reference

Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1359786806064310

Patients With Severe Depression May Benefit From Buspirone Augmentation of Selective Serotonin Reuptake Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806064310

Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806064310

Aripiprazole augmentation in treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806064310

Lithium augmentation therapy in refractory depression: clinical evidence and neurobiological mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806064310

Rapid reversal of psychotic depression using mifepristone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806064310

An open label trial of C-1073 (mifepristone) for psychotic major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806064310

A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806064310

A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806064310

Pramipexole in treatment-resistant depression: an extended follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806064310

Pramipexole augmentation of a selective serotonin reuptake inhibitor in the treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806064310

A prospective trial of modafinil as an adjunctive treatment of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806064310

A prospective trial of bupropion SR augmentation of partial and non-responders to serotonergic antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806064310

Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806064310

Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806064310

Thyroid hormone treatment of primary unipolar depression: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806064310

Bupropion Treatment of Serotonin Reuptake Antidepressant-Associated Sexual Dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806064310

Signal transduction pathways. Molecular targets for lithium's actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806064310

Is psychosis exacerbated by modafinil?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806064310

Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806064310

Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806064310

Neuropsychological deficits in psychotic versus nonpsychotic major depression and no mental illness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806064310

Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806064310

A novel augmentation strategy for treating resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806064310

Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806064310

Modafinil modulates anterior cingulate function in chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806064310

Therapeutic alternatives for difficult-to-treat depression: a narrative review of the state of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806064310

Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806064310

Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806064310

21 January 2018

Identifiers

DOI

10.1177/1359786806064310

1 reference

14 August 2017

1 reference